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Abstract 
Health care expenditure growth is affected by important unobserved common shocks 
such as technological innovation, changes in sociological factors, shifts in preferences and the 
epidemiology of diseases. While common factors impact in principle all countries, their effect 
is likely to differ across countries. To allow for unobserved heterogeneity in the effects of 
common shocks, we estimate a panel data model of health care expenditure growth in 34 
OECD countries over the years 1980 to 2012 where the usual fixed or random effects are 
replaced by a multifactor error structure. We address model uncertainty with Bayesian Model 
Averaging, to identify a small set of robust expenditure drivers from 43 potential candidates.  
We establish 16 significant drivers of healthcare expenditure growth, including growth in 
GDP per capita and in insurance premiums, changes in financing arrangements and some 
institutional characteristics, expenditures on pharmaceuticals, population aging, costs of 
health administration, and inpatient care. Our approach allows us to provide robust evidence 
to policy makers on the drivers that were most strongly associated with the growth in health 
care expenditures over the past 32 years.   
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1. Introduction 
In empirical country-level models of health care expenditure (HCE) growth great 
importance is placed on common factors. These are exogenous influences on expenditure 
growth that are unobserved but affect all countries in specific time periods. The most 
prominent common factor is technological change, in particular advances in medical care 
technology. In addition, changes in sociological factors, lifestyle, epidemiology of diseases, 
shifts in preferences of patients, and the global economic situation are potentially important 
drivers of expenditure growth that are absorbed in the common factor if they are unobserved. 
Some studies have used proxies for technological change such as R&D expenditures in all 
sectors or in health care (Okunade and Murthy, 2002), surgical procedures (Baker and 
Wheeler, 1998), the number of specific medical equipment (Weil, 1994), neonatal survival, 
or life expectancy and infant mortality (Dreger and Reimers, 2005). This is problematic 
because proxies are imperfect and results vary across studies. Therefore most studies still 
adopt variants of the ‘residual approach’ (Chernew and Newhouse, 2011, and references in 
table 1.3), which was pioneered for the economy in general by Solow (1957). It measures 
time-varying observable cost drivers, and generally attributes the rest of spending growth to 
technology and other common factors. They are captured by the residual for unobserved 
factors that are assumed to differ across countries, and by a time index (Gerdtham and 
Löthgren, 2000), time-specific intercepts (Di Matteo and Di Matteo, 1998) or year fixed 
effects (Smith et al., 2009) for factors that are assumed common.   
Panel data models of HCE growth with year fixed effects rest on the assumption that 
the association between unobserved common factors and expenditure growth is homogenous.  
This implies that the impact of common shocks is assumed to be the same in all countries, 
and that there is no association between the residual, the unobserved common factors and 
observed determinants of expenditure growth. These assumptions have been challenged by 
research demonstrating that countries differ quite markedly in the rate by which they adopt 
technological innovations in health care (Greenhalgh et al., 2008), although knowledge 
innovations are in principle accessible to all, i.e. constitute common shocks. For example, in 
the adoption of innovation in cardiac procedures countries can be classified into three 
patterns: early start and fast adoption; late start/fast adoption; and late start/slow adoption 
(Lyttkens, 2001). While the literature on HCE growth is extensive, there has not been much 
progress with incorporating these findings.  
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Our study allows for heterogeneity in the impact of common shocks, to identify the 
main drivers of HCE growth in OECD countries over the period 1980 and 2012. We estimate 
a panel data model of HCE growth where the usual fixed or random effects are replaced by a 
multifactor error structure as proposed by Pesaran (2006). The factor structure synthesizes the 
effects of shocks that may hit health spending in different time periods. While those common 
factors affect in principle all countries, our model allows for their differing impact on growth 
across countries. The theoretical literature has shown that a multifactor error structure leads 
to estimates that are less subject to bias.   
Main objective of our study is to generate estimates of the most robust drivers of HCE 
growth. What constitutes ‘most robust’ has been subject to some debate, because analysis of 
HCE growth is affected by high model uncertainty. While there is now an impressive amount 
of evidence on the individual importance of determinants (Chernew and Newhouse, 2011), 
there is little guidance for policy makers where to focus cost-containment efforts. We use 
Bayesian Model Averaging (BMA) to address model uncertainty in HCE growth analysis. It 
is a technique designed to help account for the uncertainty inherent in the model selection 
process, something which traditional econometric analysis often neglects. By averaging over 
many different competing models, BMA incorporates model uncertainty related to choice of 
regressors into conclusions about parameters and predictions. This technique allows us to 
identify a small set of highly influential expenditure drivers from the many potential 
candidates in our data. 
In summary, our study offers two methodological contributions to the analysis of 
HCE growth, to derive results that are more accurate and informative than those from 
previous studies. We use common factor modelling to allow for heterogeneity in the impact 
of common shocks, and BMA to address model uncertainty related to choice of regressors. 
The improved results are then used to inform policy makers on the magnitude of impact of 
the most robust drivers of HCE growth.   
2. Background 
Recently, the econometrics literature on panel data has focused on common factors 
that represent unobserved, time-varying heterogeneity that stems from omitted common 
variables or global shocks that affect each country or observational unit differently (Andrews, 
2005; Pesaran, 2006; Bai, 2009; Peng and Forchini, 2014).  Studies are mostly motivated by 
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modelling of economic growth. It is assumed that common shocks affect output directly 
(through the total factor productivity or Solow residual), but also indirectly via the input in 
the production process (e.g. through investment decisions). When common shocks have 
homogeneous effects on the output, the model collapses to the usual time effect. It is the 
heterogeneity that gives rise to a factor structure. Earlier contributions to the literature allow 
only for models with factor structure in the errors (Case, 1991; Conley, 1999) for which 
consistent estimation of the parameters can be done by maximum likelihood procedures or by 
estimation procedures based on principal components applied to the residuals (Coakley et al., 
2006). More recently, it has been noticed that common shocks are likely to affect both the 
dependent variable and the regressors and would thus induce endogeneity requiring more 
sophisticated estimation procedures (Andrews, 2005; Pesaran, 2006). Pesaran (2006) 
proposes estimators that are consistent when both the N and T dimensions tend to infinity.  
These results have been extended by Bai (2009) to set-ups that allow for a more complex 
dependence of the regressors on the unknown factors and factor loadings, by Su and Jin 
(2012) and Huang (2012) to semiparametric models, and by Peng and Forchini (2014) to 
models for fixed T and N tending to infinity and less restrictive conditions. 
Common factor models have an obvious application in the analysis of HCE growth 
because of the importance of common shocks.
1
 We use the model proposed by Pesaran 
(2006), because we want to allow for the possibility that heterogeneity in the impact of 
common shocks on HCE growth could -at least partly- be explained by observable factors.  
These could relate to the organization of the health system, overall income level or other 
factors. For example, insurance tends to shield patients from most of the cost of care at the 
margin and passively reimburses on a disaggregated, fee-for-service basis, which gives 
greater encouragement to quality and cost-increasing technology in insurance based systems; 
competition between providers fosters spread of quality improving and cost saving medical 
technology; higher incomes increase demand for quality and make innovations more 
profitable to introduce.  It is even possible that certain health system traits do not have a great 
effect on spending growth in themselves, in particular if they change little over time; instead, 
their impact on spending growth predominantly arises because they are correlated with the 
common factor, and it is the interaction between the observed system trait and the unobserved 
common factor which impacts on spending.   
                                                          
1
 Online Appendix I discusses alternative modelling approaches that allow for common shocks’ heterogeneous 
impacts if these common shocks are all observed. 
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Two studies have applied common factor modelling to the analysis of HCE. Baltagi 
and Moscone (2010) focus on the relation between HCE and GDP per capita, to address the 
long-standing issue of the magnitude of the income-elasticity of healthcare spending, using a 
panel of 20 OECD countries over the period 1971–2004. They control for both cross-
sectional and spatial dependence. Heterogeneity is handled through fixed effects in a panel 
homogeneous model and through a panel heterogeneous model. Mello-Sampayo and Sousa-
Vale (2014) analyse the relationship between HCE and type of financing in a panel of 30 
OECD countries from 1990 to 2009. Both studies focus on the time series properties of their 
model, and analyse absolute HCE (not growth) and only include a few regressors: population 
aged over 65 years old and under 15 years old, and proportion of government expenditure on 
total expenditure; Mello-Sampayo and Sousa-Vale (2014) also include two proxies of 
medical technology. Neither study estimates the magnitude of impact of cost drivers, the 
main objective of our study.   
Identifying determinants of expenditure growth has proven difficult because of high 
model uncertainty. A large and varied number of potential determinants of expenditures have 
been suggested (Chernew and Newhouse, 2011), but for each study that finds evidence for a 
determinant, there is at least one other study that finds evidence against. Even if there is 
consensus, there is uncertainty about the magnitude of its impact. For example, nearly all 
studies uncover rising income–generally proxied by GDP per capita- as an important cost 
driver, but estimates of the income elasticity of HCEs vary (Hartwig, 2008). Model 
uncertainty forces researchers to ignore the uncertainty surrounding the model selection 
process and base inference on an essentially arbitrary chosen subset of regressors (Moral-
Benito, 2010). We use Bayesian Model Averaging (BMA) on least squares estimation as 
proposed by Sala-i-Martin et al. (2004) extended to a panel data framework to estimate all 
model specifications given our data. We then examine whether the estimated results for any 
determinant are sufficiently stable (‘robust’) across most specifications. By doing so, we are 
considering not only the uncertainty associated with the parameter estimate conditional on a 
given model, but also the uncertainty of the parameter estimate across different models. This 
approach leads us to more reliable, or at least more honest, conclusions regarding the 
significance of the estimated effect of a determinant (Moral-Benito, 2010).   
A recent paper by Hartwig and Sturm (2014) applies frequentist model averaging to 
the analysis of HCE growth for 33 OECD countries over the period 1970–2010. They test a 
large number of macroeconomic and institutional determinants of HCE growth. Results 
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confirm earlier findings that GDP growth and a variable representing Baumol’s ‘cost disease’ 
theory emerge as robust and statistically significant determinants of HCE growth. Depending 
on whether or not outliers are excluded, there are six additional robust drivers: the growth in 
expenditure on health administration, the change in the share of inpatient expenditure in total 
HCE, the (lagged) government share in GDP, the change in the insurance coverage ratio, the 
growth in land traffic fatalities and the growth in the population share undergoing renal 
dialysis.   
3. Data 
Main data source for our study is the OECD Health Statistics (OECD, 2014), 
supplemented with institutional variables of the organisational features of healthcare systems.  
These are binary variables, obtained from Christiansen et al. (2006) and extended to the year 
2012 by us. In total, our study tests 43 determinants in 34 countries between 1980 and 2012.  
Table I lists countries and years with data available, and Table II presents variable 
descriptions and summary statistics. We broadly follow Hartwig and Sturm (2014) in choice 
of determinants, but include additional ones as suggested in the literature. We follow 
common practice and convert all level variables into growth rates and all proportion/share 
variables into first differences.   
Insert Table I Here 
The presence of missing values in the OECD data poses a problem. In order to expand the 
number of drivers that we can test for importance, and investigate changes in expenditures 
over a relatively long period from 1980 to 2012, we impute missing values for determinants 
with multiple imputation (MI) (STATA, 2013; Azur et al., 2011). We do not impute the 
dependent variable but drop country-years with missing values, thus creating an unbalanced 
panel (see Table I for available country-years). MI predicts the missing data in a manner that 
allows for uncertainty about the values of the missing data, while at the same time 
maintaining the overall covariance structure of the variables (for more details see online 
Appendix II A). This ensures that causal inferences are not being driven by the randomness 
of a given imputation. MI adjusts the standard errors in the estimated relationship, to account 
for the fact that there is additional uncertainty relating to the imputation (Rubin, 1987). 
Summary statistics presented in Table II and III show that original and imputed data are 
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sufficiently similar
2
. We only analyse determinants if less than 50% values are missing across 
country-years. In an alternative specification, we applied a cut-off at 25%, which reduces the 
number of determinants from 43 to 24. With multiple imputation, a greater uncertainty 
related to the imputation results in an increase of the standard deviation around the estimates 
and makes determinants less likely to be significant (White et al., 2011).  This implies that 
the results will reflect a weaker evidence base due to missing values, and we would argue that 
this is a desirable feature for policy decisions.  
Insert Table II Here 
Insert Table III Here 
4. Econometric Framework 
The innovative contributions of our study are to account for heterogeneity in the 
effects of common factors by allowing a multifactor error structure, and to address model 
uncertainty with the use of Bayesian Model Averaging. These innovations allow us to 
determine drivers that are most strongly associated with the growth in HCE.  A panel data 
model of HCE growth with multifactor error structure (Pesaran, 2006; Bai, 2009) can be 
written as  
 , 1,..., ;      1,..., it it i ity i N t T   x   (1) 
where yit is HCE growth in country i and time period t;  is a  vector of regressors and 
 represents the heterogeneous coefficients for the i-th country, which follow the random 
coefficient specification, i.e., , ~ IID(0, ), for 1,2i i i v i = ,...,N  v v   . The error term is 
assumed to have a multiple factor structure  
,it i t ite  f    (2) 
where  1 ,...,t t mtf f f  is a 1m  (m is normally unknown) vector of unobserved factors,  
 1 ,...,i i mi     is a 1m  vector of factor loadings and  is an idiosyncratic error with 
                                                          
2
Figure A1 in online Appendix II shows overlay plots of original and imputed data for selected variables, which 
further demonstrate imputed data are sufficiently similar to original data.  
itx 1k
i
ite
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mean of zero and assumed to be uncorrelated with the regressors in itx .
3
 While a 
conventional panel data model allows for common shocks, it makes the restrictive 
assumption that they affect all countries in the same way. The factor structure represents a 
generalization of the conventional error components approach in the sense that it allows for 
unobserved time-specific factors to affect all countries in different ways; for example, it 
allows for variations in the rates by which countries adopt or implement new technology that 
becomes generally available in specific time periods. 
Some of the causes of unobserved heterogeneity in the effects of common shocks 
remain unobserved, and would then be absorbed in the factor loadings. Therefore, in addition, 
we allow correlation of unobserved factors tf  with observable cost drivers in itx  and adopt 
the pooled common correlated effect (PCCE) estimator proposed by Pesaran (2006) to 
estimate  , the mean of heterogeneous country parameters. The PCCE estimator does not 
require estimating m, the number of unobserved latent factors (except to assume m is fixed 
and finite), and is valid when tf  are correlated with itx .It is desirable to allow for such 
correlation, because some determinants that lead to heterogeneity in the impact of 
unobservable common shocks are observed in empirical models of HCE growth. For example, 
the spread of medical technological change has been shown to correlate with well-observable 
drivers of costs such as income per capita and the extent of insurance coverage. Therefore 
unobserved shocks can be thought of as omitted variables. Failure taking them into account 
may lead to biased estimates of 's .  
Given the large number of potential growth determinants, there potentially exists an 
enormous amount of empirical models when the empirical researcher seeks to explore 
different combination of determinants. Suppose we have K potential determinants, we then 
would have a maximum of 2K  possible combinations of regressors, i.e. 2
K  models to 
estimate. Let rM  ( 1,2,...,2
Kr  ) denote the r-th model under consideration, then rM  
depends on a set of growth determinants, rX , and their corresponding coefficients
r .  Let

 be a vector of parameters that has a common interpretation in all models, i.e. 

 is a 
                                                          
3
The conventional panel data model with standard two-way error components, i.e.
it i t itu e     is a special 
case of (2) by setting 2, ( ,1)i im u    , and (1, )t tf     so that i t i tf u    , with  representing an 
individual-specific time-invariant effect and  a time-specific individual-invariant effect. 
iu
t
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function of 
r  for each 1,2,...,2
Kr  . For point estimations of  , we can take expectations 
of the posterior densities of the parameters of all models under consideration, and obtain  
2
1
( | ) ( | ) ( | , ),
K
r r
r
E p M E M

y y y   (3) 
where the posterior probability of , i.e. ( | )rp M y , assesses the degree of support for 
model rM , and ( | , )rE My  is the posterior expectation of   under model rM . 
Following Leamer (1978), the posterior variance of  is given by  
 
2 2
2
1 1
Var( | ) ( | )Var( | , ) ( | ) ( | , ) ( | ) .
K K
r r r r
r r
p M M p M E M E
 
   y y y y y y      (4) 
The posterior variance of   incorporates not only the weighted average of estimated 
variances from each individual model, but also the weighted variances in estimates of   
across different models. Following Sala-i-Martin et al. (2004), we apply the so-called BACE 
(Bayesian Averaging of Classical Estimates) approach. In this approach, a diffuse prior is 
assumed for a given model rM , therefore Bayesian posterior expectations of   are 
identical to the classical estimation from OLS. Then Equation (3) can be rewritten as  
2
1
ˆ( | ) ( | ) ,
K
r
r
r
E p M

y y                                   (5) 
where ˆ
r
 is the generic OLS estimator for 
  from model rM . By applying common factor 
model to our study, ˆ
r  is the PCCE estimator. 
The logic of Bayesian inference is to obtain results for every possible model given the 
data, and average them. The weights in the averaging are the posterior model probabilities. 
The logic is straightforward, but implementation can be difficult when 2K  (the number of 
models under consideration) is large. It is then practically impossible to incorporate every 
possible model in the averages as given by Equations (3) and (4). This has led to the 
development of various algorithms that do not require estimating all possible models and 
instead approximate results (Madigan, et al. 1995; George and McCulloch 1993; Geweke 
rM

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1999; Clyde, et al. 1996). In this study we adopt the ‘stratified sampling’4 method proposed 
by Sala-i-Martin, et al. (2004).More details on Bayesian Model Averaging are provided in 
online Appendix II B.   
5. Results 
Table IV presents results for robust regressors from Bayesian model averaging over 
common factor (CF) models in panel A. For comparison, results from fixed-effect models 
(with both individual country effects and year effects) are presented in panel B. Results for 
posterior means and posterior standard deviations conditional on inclusion are as calculated 
by Equation (3) and (4) respectively. From the posterior density we estimate the posterior 
probability that a variable’s coefficient has the same sign as its posterior mean conditional on 
inclusion, which is indicated as “Sign Certainty Probability”.  If sign certainty is above 95%, 
then the coefficient would be 10-percent significant in a two-tail test in classical terms, and 
we can be 90% confident that the variable is a robust driver of HCE. We further report the 
fraction of specifications for which the absolute value of a determinant’s t-statistic is larger 
than 2.
5
 Table AII in online Appendix II presents results for the model with variables that 
have less than 25% missing values. In the following discussion we do not mention the 25% 
sample results if the respective variable was either excluded from analysis, or not robust.  
Insert Table IV Here 
Results on robustness do not directly inform on the policy importance of a 
determinant. Estimates of the magnitude of impact of robust determinants on HCE growth are 
compared in Table IV. This shows the percentage change in growth rate associated with a one 
within-country standard deviation (SD) change of the determinant.  We use a one SD change 
in determinants -instead of a one unit change- to makes determinants comparable that are 
measured in different units or that vary in range. Results for determinants that are not robust 
are presented in figure 1.
6
 Sign certainty is plotted on the x-axis, and in order to allow 
interpretation as ‘Probability of determinant being positive’, the values are subtracted from 
unity for determinants with a negative posterior mean. The fractions of significant 
specifications are plotted on the y-axis.  
Insert Figure 1 Here 
                                                          
4
 For technical details, please refer to Sala-I-Martin et al. (2004) and its Technical Appendix. 
5
 For ease of exposition referred to as ‘significance’ in the remainder of the paper. 
6
 The full estimation results are presented in Table AII in online Appendix II. 
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We can identify 16 robust variables from the CF models (7 robust variables for the 25% 
models). Growth in GDP is positively associated with expenditure growth, confirming results 
from many previous studies that income is a critical factor in determining how much nations 
spend on medical care (Chernew and Newhouse, 2011). It consistently explains around 90% 
of variation in real health spending across countries and time (Smith et al., 2009). Empirical 
estimates tend to find a macro-level income elasticity of about 1.0 after adjusting for other 
factors that are correlated with GDP such as technology, medical prices and insurance, 
implying that health spending moves in tandem with GDP (Gerdtham and Jönsson, 2000). 
More recent studies estimate elasticities of below one, suggesting the necessity nature of 
healthcare (Dreger and Reimers, 2005; Baltagi and Moscone, 2010).  This is confirmed by 
our results; a one SD increase in GDP growth rate is associated with a .77 increase in HCE 
growth rate. The posterior means of GDP from the 50% and 25% models are nearly identical.  
Growth in insurance premiums for private and social insurance is positively 
associated with growth in HCE; insurance payments make up part of measured healthcare 
expenditures, and growth in premiums are likely to directly translate into HCE growth.  
Impact is largest among all robust regressors at a 1.31 increase in HCE growth. However, 
changes in the two variables that capture the proportion of health expenditures funded by 
social and private insurance are negatively associated with HCE growth; i.e. countries that 
have re-oriented their health system towards a greater role of social or private insurance in 
financing, and by default a smaller role for public financing, have experienced a reduction in 
HCE growth. According to our results, increases lead to 0.96 and 0.51 reductions in HCE 
growth, respectively. Research on the expenditures impact of social and private health 
insurance is conflicting, for a discussion in the context of OECD countries see Colombo and 
Tapay (2004). On the one hand, private insurers operating in a competitive market may 
improve efficiency in administering insurance plans and enforce pressures on health service providers 
to minimise costs. On the other hand, coverage provided by multiple competing insurers can be 
administratively costly, and market failures resulting from information asymmetries and moral hazard 
may ultimately increase costs.Our results for private insurance would support the first line of 
arguments. Tax financed systems are generally less regressive than systems relying on 
insurance for financing, in particular private insurance, because contributions can be spread 
over a larger share of the population (Wagstaff et al., 1999). The dampening impact of a 
greater role for insurance financing on HCE growth may therefore come at a political cost of 
increased inequality. For a discussion, see (Chernew and May).  
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An increase in pharmaceutical sales per capita is positively associated with healthcare 
expenditure growth. Pharmaceuticals account for almost a fifth of all health spending on 
average across OECD countries (Docteur et al., 2008), and diffusion of new drugs has been 
an important factor contributing to increased pharmaceutical expenditure and overall HCE 
(Docteur et al., 2008; Clemente et al., 2008). However, the relationship between 
pharmaceutical spending and total health spending is a complex one, in that increased 
expenditure on pharmaceuticals to tackle diseases may be offset by reduced morbidity, less 
need costly interventions in future, and overall improved health outcomes (Dormont et al., 
2006). This is not an effect we can analyse, and we find the impact of pharmaceuticals to be 
comparably high at 0.83 increase in HCE growth. An increase in the proportion of the 
population above 65 years is associated with an increase in HCE growth at0.4.The posterior 
mean is very similar in the 25% sample (2.82 versus 3.00). A straightforward explanation 
seems to be the greater morbidity among the elderly population, but some have contested this 
based on evidence that the impact of age disappears once proximity to death is controlled for 
(Zweifel et al., 2004). Healthcare resource use is most intense in the few months before death, 
and medical expenses during additional life years spent in relatively good health may hardly 
impact on overall lifetime spending. The unemployment rate is negatively associated with 
expenditure growth, i.e. an increase in the unemployment rate is associated with a decrease in 
HCEs. Unemployment rises in times of financial crises, and associated reductions in tax 
revenue and increases in the social budget devoted to unemployment benefits and other social 
contributions have been found to reduce public funds for healthcare (Cylus et al., 2012;de 
Belvis et al., 2012). Similarly, recessions slow the growth in wages with negative impact on 
private healthcare expenditures. Growth in public spending on education and expenditures of 
general government are positively associated with healthcare spending, indicating that 
spending across different public services is complementary rather than substitutive. 
Associations are 0.46 and 0.34, but the determinants are significant in only 88% and 53% of 
all specifications.  
Inpatient care discharges and acute care beds are positively associated with HCE 
growth. Most countries have made efforts to substitute inpatient care with less costly 
outpatient and day case treatments, and our result show that countries which were more 
successful with this substitution have indeed profited from a slower growth in HCE. 
Reductions are associated with0.35and 0.28reductions in HCE growth (at low significance 
for beds though). This result is confirmed by previous findings (Docteur and Oxley, 2003). 
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An increase in the costs of expenditures on health administration is positively associated with 
expenditure growth although the effect is small at 0.35. Our results confirm previous 
evidence (Hartwig and Sturm, 2014). In some countries, administration account for a sizable 
proportion of the health care budget. Highest costs are recorded for the USA, at around 31.0 
percent of HCE in the United States. Rates are lower in most other countries, for example just 
under 17% in Canada (Woolhandler et al., 2003).The authors have estimated that moving to a 
Canadian-style social insurance system would reduce U.S. administrative costs by 10–15 
percent of total health spending, confirming our result. Inpatient expenditure is negatively 
associated with HCE. This is a counterintuitive result that is difficult to explain, and also 
found by Hartwig and Sturm (2014), however, it is significant in less than 80% of 
specifications. Tobacco consumption has a robust positive association with HCE growth, but 
only 46% of specifications are significant.  
A change towards, or away from, capitation remuneration and a public contract 
healthcare system are the only institutional determinants associated with a robust increase, or 
decrease, in HCE growth, however the effects are small at 0.22 and 0.05, and less than 90% 
of specifications are significant. The posterior means are very similar for the 25% models; for 
capitation 2.35 (versus 1.92), and for public contract systems 2.35 (versus 2.30). Capitation is 
usually considered as cost-containing, which is not supported by our result. However, it has 
been found that there are great variations in the way capitation is implemented (Rice and 
Smith, 2001). Public contract systems are generally considered less successful in containing 
healthcare cost than public integrated systems, mainly because payment of providers is ex-
post (Docteur and Oxley, 2003). This is confirmed by our finding. None of the other 
institutional variables are significant drivers of healthcare expenditures. This could be due to 
difficulties of measuring health system characteristics in binary variables, and also because 
there is relatively little change in such characteristics over time, and identification has mainly 
to rely on cross country variation.   
There are a few determinants that nearly reach robustness and statistical significance 
(see figure 1). These are choice of hospital, GP or specialist, road traffic accidents and 
alcohol consumption, and at lower levels of significance, R&D expenditures and insurance 
coverage. Apart from those, sign certainty and fraction significant are low for the remaining 
determinants. Results from fixed effects and CF models are very similar, although four 
determinants are robust according to CF but not FE models, and one robust according to FE 
but not CF model. 
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6. Conclusions 
Empirical models of healthcare expenditure growth are affected by at least three 
problems: unobserved heterogeneity in the effect of common shocks across countries, high 
model uncertainty, and missing data. Economic theory has shown that these problems may 
lead to bias in the estimates of the impact of observable cost drivers, and could be partly 
responsible for the relative wide variations in results that have been found in the literature. 
Objective of our study is to address these problems by applying novel econometric methods 
that have been developed in the empirical economic growth literature. The innovative 
contributions of our study to the analysis of HCE growth are, first, to adopt panel data models 
with a multifactor error structure (Pesaran, 2006; Bai, 2009) that allows for variations in the 
impact of common shocks on HCE growth across countries; second, to apply Bayesian model 
averaging methods (Koop et al., 2007) that address model uncertainty and identify robust 
drivers of healthcare expenditure growth; third, to use multiple imputation techniques (Rubin, 
1987) that incorporate the uncertainty surrounding the imputation into final model estimates. 
We compare our results with a standard fixed effects model of HCE growth, and find that 
estimates are very similar, at least for the most robust determinants. This lets us conclude that 
despite the supremacy of CF models on theoretical grounds, in this practical application a 
standard FE model seems perfectly adequate. The finding could also mean that there is 
homogeneity in the impact of common shocks, or that the CF model is unable to correct for 
heterogeneity, in our application.  
Our analysis has limitations. For many of our results it would be erroneous to infer a 
direct causal relation between a change in the determinant and impact on HCE growth. Some 
determinants may act as proxies for others that are not included in the models, or the 
relationship is highly complex and influenced by other factors. Our data is affected by 
unobserved variables and missing data. Although the OECD Health Statistics is the preferred 
dataset for analysis of HCE growth, some important drivers, in particular institutional 
variables, are poorly represented. Our results are based on historical trends over the past 32 
years, and may not apply to the coming 32 years. Pesaran’s estimator makes the implicit 
assumption that is that the error cross-section dependence in large N and large T panels can 
be explained by exogenously given unobserved factors which are essentially treated as 
nuisance parameters that have no informational content. The extensive previous literature on 
healthcare expenditure growth largely rests on the assumption that there is no cross-section 
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dependence at all. Therefore we consider our approach an improvement over previous studies, 
but of course we acknowledge that future research should address this issue. Bayesian Model 
Averaging does not address model uncertainty related to functional form, and it is subject to 
the available data. 
Despite the limitations, we can derive some conclusions. A greater reliance on private 
and social insurance, as opposed to public financing, seems to dampen growth. Competitive 
pressures in insurance markets seem to be associated with greater efficiency. Tackling the 
costs of pharmaceuticals, by regulation of the pharmaceuticals and devices markets, is 
another promising policy according to our results. Similarly, slimming health administration 
is predicted to curtail growth. Organisational reforms of the healthcare system should be 
directed to increase efficiency of the management of healthcare provision; further research is 
necessary to establish at what managerial level greatest efficiency gains can be expected. We 
further find that substitution of inpatient with outpatient care can reduce HCE growth, a 
policy that has been fostered by most countries in our study. Characteristics of the healthcare 
system and health indicators show weak associations with HCE growth, but it is important to 
keep in mind that these factors may still have an association with the level of expenditures. 
Overall, we hope that our results provide robust evidence to policy makers on the drivers that 
are most strongly associated with the growth in HCE, and will be used to inform effective 
policies in OECD countries.   
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Table I List of OECD Countries and Years Included in the Study 
 
Country Year 
Australia 1981-2010 
Austria 1981-2011 
Belgium 1981-2011 
Canada 1981-2012 
Chile 1996-2012 
Czech Republic 1991-2011 
Denmark 1981-2011 
Estonia 2000-2011 
Finland 1981-2012 
France 1991-2011 
Germany 1981-1990, 1993-2011 
Greece 1988-2011 
Hungary 1992-2012 
Iceland 1981-2012 
Ireland 1981-2011 
Israel 1981-2011 
Italy 1989-2012 
Japan 1981-2010 
Korea 1981-2012 
Luxembourg 1996-2011 
Mexico 1991-2010 
Netherlands 1981-2011 
New Zealand 1981-2011 
Norway 1981-2012 
Poland 1991-2011 
Portugal 1981-2011 
Slovak Republic 1998-2011 
Slovenia 1996-2012 
Spain 1981-2011 
Sweden 1981-2011 
Switzerland 1981-2012 
Turkey 1981-2008 
United Kingdom 1981-2011 
United States 1981-2011 
Note: Country-years with missing values on healthcare expenditure growth are excluded from analysis. 
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Table II Descriptive Statistics for the Original Data Set 
Variable Description Obs 
% of 
missing 
values 
Mean Std. Dev. Min Max 
lnhce Total expenditure on health (per capita, NCU at 2005 GDP price level) 909 0.00% 3.37 4.82 -28.33 29.42 
lnacc Road traffic accidents (injured per million population) 839 7.70% -0.93 7.91 -76.37 30.17 
lnalc Alcohol consumption (ltr per capita, ages 15+) 846 6.93% -0.36 5.12 -32.54 30.01 
lnbsi Acute care beds (per 1,000 population) 628 30.91% -1.63 3.70 -29.09 34.80 
pbirt Births, live (per 1,000 population) 889 2.20% -0.11 0.42 -3.10 3.70 
pcanm Neoplasms, deaths (per 100,000 population) 831 8.58% -1.39 5.36 -26.20 27.90 
pcove Insurance coverage (% of population) 752 17.27% 0.24 1.90 -5.10 36.40 
pfpr Labor force participation rate, female (% of female population ages 15+) 552 39.27% 450.90 89.18 100.87 666.70 
lngdp Gross domestic product (per capita, US$ at 2005 PPP) 909 0.00% 4.83 3.53 -10.37 19.38 
lnger R&D expenditures (million of US$ at 2005 PPP) 592 34.87% 5.04 7.39 -35.35 49.68 
pgp1 Public coverage of health care (% of total population) 808 11.11% 0.27 1.93 -5.10 37.40 
lngp Generalist medical practitioners (per 1,000 population) 457 49.72% 0.01 0.06 -0.53 0.55 
pgsh Expenditure of general government, total (% of GDP) 645 29.04% 0.01 2.35 -18.42 17.34 
phemp Health and social employment (% total employment) 495 45.54% 0.12 0.47 -2.51 5.49 
lnhospc General hospitals (per 1,000 population) 525 42.24% -1.74 5.37 -39.01 36.85 
lninp Inpatient care discharges, all hospitals (per 100,000 population) 610 32.89% 0.43 3.43 -27.66 16.55 
lnlos Length of stay in hospital, all causes (average days) 504 44.55% -1.64 4.74 -33.85 21.67 
lnmt Life-years lost (all causes per 100,000 population, 0-69 years) 816 10.23% -2.49 3.19 -21.98 18.71 
lnpha Pharmaceutical sales (per capita, US$ at 2005 PPP) 456 49.83% 5.60 6.59 -22.99 32.99 
lndoc Physicians (per 1,000 population) 579 36.30% 1.97 6.06 -34.79 65.68 
lnins Insurance premiums, private and social (per capita, US$ at 2005 PPP) 517 43.12% 4.12 7.47 -54.36 34.69 
ppins Private insurance expenditure (% total health expenditure) 577 36.52% 0.07 0.57 -7.76 3.17 
ppop6 Population above 65 years (% total population) 899 1.10% 0.15 0.17 -0.70 1.00 
ppop8 Population above 80 years (% total population) 876 3.63% 0.07 0.08 -0.50 0.40 
ppuhe Health expenditure, public (% total health expenditure) 762 16.17% -0.03 2.04 -16.10 15.10 
pedx Public spending on education, total (% of government expenditure) 515 43.34% 0.04 0.71 -4.61 3.43 
psss Social insurance expenditure (% total health expenditure) 626 31.13% -0.04 1.86 -23.10 10.72 
lnta Health administration, expenditures (per capita, NCU at 2005 GDP price level) 477 47.52% 4.25 22.27 -150.41 248.49 
ptexm Inpatient expenditures (% total health expenditure) 594 34.65% -0.41 2.44 -22.00 9.70 
lntob Tobacco consumption (grams per capita, age 15+) 624 31.35% -2.02 7.04 -64.34 53.54 
lndp Population density (per km2) 909 0.00% 0.67 0.68 -3.96 6.01 
punem Unemployment rate, total (% civilian labour force) 675 25.74% 0.09 1.25 -4.45 8.27 
lnle Life expectancy at age 65 (total) 885 2.64% 0.85 1.22 -4.85 7.87 
mic Middle income country 909 0.00% 0.18 0.39 0.00 1.00 
capit Capitation remuneration (primary care) 909 0.00% 0.14 0.34 0.00 1.00 
caseh Fee-for-service (in-patient care) 909 0.00% 0.17 0.38 0.00 1.00 
copay Copayment for GP or hospital 909 0.00% 0.72 0.45 0.00 1.00 
ffsa Fee-for-service (primary care) 909 0.00% 0.29 0.46 0.00 1.00 
free Choice of hospital, GP or specialist 909 0.00% 0.97 0.18 0.00 1.00 
gatek Gatekeeper GPs 909 0.00% 0.52 0.50 0.00 1.00 
globu Global Budgets (in-patient care) 909 0.00% 0.33 0.47 0.00 1.00 
hcspc Public contract healthcare system 909 0.00% 0.53 0.50 0.00 1.00 
mixgp Mix of capitation and fee-for-service (primary care) 909 0.00% 0.30 0.46 0.00 1.00 
ws Salary renumeration (primary care) 909 0.00% 0.20 0.40 0.00 1.00 
Notes: Summary statistics are calculated across countries and years; level variables are converted into growth rates and prefixed “ln”; 
proportion/share variables are first differenced and prefixed “p”. 
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Table III Descriptive Statistics for Two Imputed Data Sets 
 
1st Imputed data set 50th Imputed data set 
Variable Mean Std. Dev. Min Max Mean Std. Dev. Min Max 
lnacc -1.26 9.02 -76.37 30.17 -1.00 8.65 -76.37 30.17 
lnalc -0.37 5.05 -32.54 30.01 -0.34 5.10 -32.54 30.01 
lnbsi -1.32 4.05 -29.09 34.80 -1.33 4.51 -29.09 34.80 
pbirt -0.12 0.42 -3.10 3.70 -0.11 0.43 -3.10 3.70 
pcanm -1.15 5.93 -26.20 27.90 -1.31 5.38 -26.20 27.90 
pcove 0.25 1.82 -5.10 36.40 0.27 1.91 -5.10 36.40 
pfpr 454.78 92.36 100.87 666.70 454.41 89.99 100.87 666.70 
lngdp 4.83 3.53 -10.37 19.38 4.83 3.53 -10.37 19.38 
lnger 6.03 8.50 -35.35 49.68 4.99 8.98 -35.35 49.68 
pgp1 0.32 1.92 -5.10 37.40 0.32 1.95 -5.10 37.40 
lngp 0.02 0.08 -0.53 0.55 0.01 0.08 -0.53 0.55 
pgsh -0.03 3.12 -18.42 17.34 -0.09 2.72 -18.42 17.34 
phemp 0.15 0.60 -2.51 5.49 0.14 0.58 -2.51 5.49 
lnhospc -2.27 6.58 -39.01 36.85 -1.73 5.53 -39.01 36.85 
lninp 0.40 3.67 -27.66 16.55 0.92 4.69 -27.66 16.55 
lnlos -2.52 5.06 -33.85 21.67 -2.23 5.24 -33.85 21.67 
lnmt -2.44 3.24 -21.98 18.71 -2.47 3.22 -21.98 18.71 
lnpha 7.00 7.62 -22.99 32.99 6.72 6.59 -22.99 32.99 
lndoc 1.77 6.80 -34.79 65.68 1.91 6.34 -34.79 65.68 
lnins 4.41 9.65 -54.36 34.69 4.16 8.75 -54.36 34.69 
ppins 0.05 0.64 -7.76 3.17 0.07 0.61 -7.76 3.17 
ppop6 0.15 0.17 -0.70 1.00 0.15 0.17 -0.70 1.00 
ppop8 0.07 0.08 -0.50 0.40 0.07 0.08 -0.50 0.40 
ppuhe -0.04 1.96 -16.10 15.10 0.01 2.02 -16.10 15.10 
pedx 0.08 0.81 -4.61 3.43 0.08 0.86 -4.61 3.43 
psss -0.05 2.17 -23.10 10.72 -0.10 1.97 -23.10 10.72 
lnta -0.61 32.85 -150.41 248.49 0.64 31.03 -150.41 248.49 
ptexm -0.51 2.92 -22.00 9.70 -0.25 2.83 -22.00 9.70 
lntob 0.55 11.58 -64.34 53.54 -2.71 7.35 -64.34 53.54 
lndp 0.67 0.68 -3.96 6.01 0.67 0.68 -3.96 6.01 
punem 0.04 1.22 -4.45 8.27 0.14 1.23 -4.45 8.27 
lnle 0.83 1.31 -9.33 7.87 0.82 1.30 -6.57 7.87 
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Table IV Bayesian Model Averaging Estimation Results for Robust Determinants of Healthcare Expenditure Growth 
    A. Common factor models B. Fixed effect models 
Determinant 
 
Impact on 
HCE 
growth(SD 
change) 1 
Posterior 
Mean 
Posterior 
Standard 
Deviation 
Sign Certainty 
Probability2 
Fraction of 
Regressions 
with |tstat|>2 
Posterior 
Mean 
Posterior 
Standard 
Deviation 
Sign Certainty 
Probability 
Fraction of 
Regressions 
with 
|tstat|>2 
Insurance premiums, private and social (per 
capita, US$ at 2005 PPP) 
lnins 1.31 0.2220***3 0.0556 1 1 0.2143*** 0.057 1 1 
Social insurance expenditure (% total health 
expenditure) 
psss -0.96 -0.8086*** 0.1746 1 1 -0.8320*** 0.1793 1 1 
Pharmaceutical sales (per capita, US$ at 2005 
PPP) 
lnpha 0.83 0.1537*** 0.0408 0.9997 0.9987 0.1449*** 0.0413 0.9993 0.9958 
Unemployment rate, total (% civilian labour 
force) 
punem -0.81 -0.7289*** 0.1779 0.9998 0.9995 -0.7932*** 0.2 0.9998 1 
Gross domestic product (per capita, US$ at 
2005 PPP) 
lngdp 0.77 0.2329*** 0.0814 0.9955 0.971 0.2589*** 0.0794 0.9978 0.9767 
Private insurance expenditure (% total health 
expenditure) 
ppins -0.51 -1.3837*** 0.6674 0.9982 0.9987 -1.3412*** 0.6805 0.9971 0.9998 
Public spending on education, total (% of 
government expenditure) 
pedx 0.46 0.7309** 0.3136 0.9883 0.8765 0.7337** 0.3545 0.9782 0.7834 
Population above 65 years (% total 
population) 
ppop6 0.40 3.0026** 1.1341 0.9932 0.9413 2.4764* 1.229 0.9746 0.6468 
Health administration, expenditures (per 
capita, NCU at 2005 GDP price level) 
lnta 0.35 0.0196*** 0.0071 0.9953 0.9884 0.0201** 0.0085 0.9888 0.9779 
Inpatient care discharges, all hospitals (per 
100,000 population) 
lninp 0.35 0.1324** 0.0566 0.9891 0.9202 0.1481** 0.0656 0.9858 0.9151 
Expenditure of general government, total (% 
of GDP) 
pgsh 0.34 0.1626* 0.0916 0.9658 0.5331 0.2032* 0.1068 0.9724 0.4769 
Inpatient expenditures (% total health 
expenditure) 
ptexm -0.34 -0.1617* 0.0802 0.9719 0.7905 - - - - 
Acute care beds (per 1,000 population) lnbsi 0.28 0.0954* 0.0507 0.9659 0.5511 0.1318** 0.0634 0.9779 0.7393 
Tobacco consumption (grams per capita, age 
15+) 
lntob 0.25 0.0408* 0.0225 0.9619 0.4578 - - - - 
Capitation remuneration (primary care) capit 0.22 1.9228* 1.0495 0.9700 0.8720 - - - - 
Public contract healthcare system hcspc 0.05 2.2973** 1.0279 0.9815 0.8957 - - - - 
Salary remuneration (primary care) ws - - - - - -1.9581* 1.0934 0.9601 0.5446 
Notes: 1 Impact is measured as the % change in HCE growth rate associated with a one SD change in the determinant; SD is calculated across years within country. 
2 Posterior probability that a variable has the same sign as its posterior mean conditional on inclusion 
3*** indicates that variable has robust impact on health expenditure growth at 1% significant level, ** for 5%, and * for 10%. 
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Figure 1 Non-robust Determinants of Healthcare Expenditure Growth 
Note: Figure displays only determinants with sign certainty <0.95 and >0.05; sign certainty is increasing towards the right (for positive determinant) and left (for negative determinants); significance is increasing towards 
the top of the figure.
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